This is an investigator-initiated, open-label, single-arm, dose-escalation exploratory study to evaluate the safety, tolerability, and preliminary efficacy of EBV-AST cell injection in adults with EBV-associated lymphoproliferative disorders, including post-transplant lymphoproliferative disease (PTLD) and EBV-positive lymphomas. Participants will receive EBV-AST cell infusions intravenously every 2 weeks for up to 3 infusions at escalating dose levels. The primary objective is to assess safety and determine a potential optimal biologically active dose. Secondary objectives include preliminary tumor response and EBV-related virologic outcomes, as well as cellular PK/PD.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Dose-Limiting Toxicities (DLTs)
Timeframe: From first infusion (Day 0) through Day 28
Safety: Incidence of Adverse Events
Timeframe: From first infusion (Day 0) through 12 months after first infusion
Recommended/Optimal Biologically Active Dose (OBD)
Timeframe: Up to 28 days after first infusion for DLT evaluation; overall dose decision through study completion